Navigation Links
Regeneron Announces Clinical Presentations at ASRS 2011 Annual Meeting
Date:8/17/2011

TARRYTOWN, N.Y., Aug. 17, 2011 /PRNewswire/ -- Regeneron Pharmaceuticals, Inc. (Nasdaq: REGN) today announced that clinical data from four separate clinical studies of EYLEA™ (aflibercept injection) will be presented at the upcoming American Society of Retina Specialists (ASRS) meeting on Sunday, August 21 and Monday, August 22, 2011 in Boston, Massachusetts.

The presentations are:

  • "Analysis of 2,457 Patients in the Phase 3 VIEW 1 and VIEW 2 Studies Comparing VEGF Trap-Eye and Ranibizumab in Neovascular AMD" will be presented by Jeffrey S. Heier, M.D. on Sunday, August 21 at 8:21 a.m.  

  • "One-year Results of the DA VINCI Study of VEGF Trap-Eye in DME" will be presented by Diana V. Do, M.D. on Sunday, August 21 at 2:48 p.m.  

  • "The 6-Month (Primary Endpoint) Results of the Phase 3 GALILEO Study: VEGF Trap-Eye in CRVO" will be presented by Jean-Francois Korobelnik, M.D. on Monday, August 22 at 8:20 a.m.  

  • "Trap-Eye in CRVO: 1-year Results of the Phase 3 COPERNICUS Study" will be presented by W. Lloyd Clark, M.D. on Monday, August 22 at 8:28 a.m.  

  • About EYLEA™ (aflibercept injection)Vascular Endothelial Growth Factor (VEGF) is a naturally occurring protein in the body.  Its normal role in a healthy organism is to trigger formation of new blood vessels (angiogenesis) supporting the growth of the body's tissues and organs.  However, in certain diseases, such as age-related macular degeneration, it is also associated with the growth of abnormal new blood vessels in the eye, which exhibit vascular permeability and lead to edema.  

    EYLEA, also known as VEGF Trap-Eye, is a fully human fusion protein, consisting of portions of VEGF receptors 1 and 2, that binds all forms of VEGF-A along with the related Placental Growth Factor (PlGF).  EYLEA is a specific and hi
    '/>"/>

    SOURCE Regeneron Pharmaceuticals, Inc.
    Copyright©2010 PR Newswire.
    All rights reserved

    Page: 1 2 3

    Related medicine technology :

    1. Bayer and Regeneron Dose First Patient in Second Phase 3 Study for VEGF Trap-Eye in Wet Age-Related Macular Degeneration
    2. Bayer and Regeneron Extend Development Program for VEGF Trap-Eye to Include Central Retinal Vein Occlusion
    3. Enrollment Completed in Regeneron and Bayer HealthCare Phase 3 Studies of VEGF Trap-Eye in Neovascular Age-Related Macular Degeneration (Wet AMD)
    4. Regeneron Announces Presentation at the 18th Annual Credit Suisse Healthcare Conference
    5. Regeneron Reports Third Quarter 2009 Financial and Operating Results
    6. Sanofi-aventis and Regeneron Expand Strategic Antibody Collaboration
    7. Regeneron Announces Presentation at the Deutsche Bank 2009 Biotech Boston Confab
    8. BioMed Realty Trust Signs New Lease With Regeneron Pharmaceuticals for 131,000 Square Feet at Landmark
    9. Regeneron Announces Presentation at the Morgan Stanley Global Healthcare Conference
    10. Regeneron Announces Presentation at the UBS Global Life Sciences Conference
    11. Regeneron Announces Panel Discussion at Citis 5th Annual Biotech Day
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:1/15/2014)... ChinaMarketResearchReports.com adds "China Orthopedic Instrument Industry Report, 2013-2015" research ... http://photos.prnewswire.com/prnh/20140115/MN46792 ) Benefiting from aging of ... orthopedic instrument industry has seen rapid development ... 3.28 billion yuan in 2006 to 9.85 billion yuan ...
    (Date:1/15/2014)... As health officials across the Midwest warn against the ... Michigan will offer free diagnostic testing ... pharmacists to administer tests and, in some cases, fill the ... in the study. The Grand Rapids, ...
    (Date:1/15/2014)... Jan. 15, 2014  Celsion Corporation (the "Company") (NASDAQ: ... from institutional investors to purchase an aggregate of approximately ... at-the-market registered direct offering, led by a dedicated health ... purchase agreements with these investors pursuant to which the ...
    Breaking Medicine Technology:Orthopedic Instrument Industry in China Markets Forecast to 2015 2Orthopedic Instrument Industry in China Markets Forecast to 2015 3Meijer Pharmacy Offers Free Flu, Strep Testing as Influenza Cases Rise Across the Midwest 2Meijer Pharmacy Offers Free Flu, Strep Testing as Influenza Cases Rise Across the Midwest 3Celsion Corporation Announces $15 Million At-The-Market Registered Direct Offering 2Celsion Corporation Announces $15 Million At-The-Market Registered Direct Offering 3
    ... Amgen (Nasdaq: AMGN ) today announced the ... of 1,776 advanced cancer patients with different types of ... multiple myeloma, which compared XGEVA ™ (denosumab) to ... study, which appeared today in the Journal of ...
    ... drugstore.com, inc. (Nasdaq: DSCM ), ... skincare, and vision products, today announced that the ... events with the financial community: (Logo: ... Telecom Conference Date: February 28, 2011Time: 3:20 p.m. ...
    Cached Medicine Technology:The Journal of Clinical Oncology Publishes Phase 3 XGEVA™ (Denosumab) Results in Advanced Cancer Patients With Solid Tumors or Multiple Myeloma 2The Journal of Clinical Oncology Publishes Phase 3 XGEVA™ (Denosumab) Results in Advanced Cancer Patients With Solid Tumors or Multiple Myeloma 3The Journal of Clinical Oncology Publishes Phase 3 XGEVA™ (Denosumab) Results in Advanced Cancer Patients With Solid Tumors or Multiple Myeloma 4The Journal of Clinical Oncology Publishes Phase 3 XGEVA™ (Denosumab) Results in Advanced Cancer Patients With Solid Tumors or Multiple Myeloma 5The Journal of Clinical Oncology Publishes Phase 3 XGEVA™ (Denosumab) Results in Advanced Cancer Patients With Solid Tumors or Multiple Myeloma 6The Journal of Clinical Oncology Publishes Phase 3 XGEVA™ (Denosumab) Results in Advanced Cancer Patients With Solid Tumors or Multiple Myeloma 7The Journal of Clinical Oncology Publishes Phase 3 XGEVA™ (Denosumab) Results in Advanced Cancer Patients With Solid Tumors or Multiple Myeloma 8drugstore.com to Present at Upcoming Financial Conferences 2
    (Date:7/9/2014)... hidden ways that cells are regulated, scientists at Rockefeller ... cells more likely to metastasize. , What,s more, the ... blocking two other proteins that are normally linked to ... could have unexpected ties. , The study, which ... , points to the possibility of new cancer therapies ...
    (Date:7/9/2014)... More scientific research into the metabolism of stromal support ... the metabolism of these cell types in the development ... diabetes, inflammatory conditions and cancer. That was the conclusion ... KU Leuven in the leading journal Nature . ... sort of wake-up call. The metabolism of cancer cells ...
    (Date:7/9/2014)... that fecal transplantation is effective and safe for treating ... the result of a study led by Colleen Kelly, ... Medicine at The Women,s Medicine Collaborative. The study and ... print in the American Journal of Gastroenterology . ... , has increased to epidemic proportions over the past ...
    (Date:7/9/2014)... R.I. -- Researchers from The Miriam Hospital ... disease (COPD) who are also depressed have difficulty ... to be particularly true for women, and screening ... as part of treatment. The study and its ... Medicine . , Chronic obstructive pulmonary disease ...
    (Date:7/9/2014)... . By looking ... brain structure and function, personality, life experiences and genetics, researchers ... develop binge drinking within the next two years. Impulsivity, hopelessness, ... life events and a family history of drug use contribute ... the child had had a single drink at age 14 ...
    Breaking Medicine News(10 mins):Health News:Protein pushes breast cancer cells to metastasize 2Health News:Protein pushes breast cancer cells to metastasize 3Health News:Wake-up call for more research into cell metabolism 2Health News:Women's Medicine Collaborative examines safety of fecal transplant to treat C. difficile 2Health News:Miriam Hospital study examines effect of depressed mood on pulmonary rehab completion 2Health News:What drives a child to abuse alcohol? 2
    ... HMSY ) today announced that it will present at the ... held May 18 - 19, 2009 at the InterContinental Hotel ... at 12:00 p.m. ET. HMS Holdings Corp. is the nation,s ... services for government healthcare programs. HMS serves the Medicaid programs ...
    ... May 13 A multi-million dollar gift from ... the University of Rochester Medical Center,s ... center for investigating and treating neurological conditions such ... and trauma to the brain and spinal cord. ...
    ... American Massage Therapy Association(R) (AMTA(R)) views the decision by ... opportunity to clarify for the public that prostitutes who ... "The public and massage therapists have a right to ... right of massage therapists," says Judy Stahl, AMTA President. ...
    ... IPC The Hospitalist Company, Inc. (Nasdaq: IPCM ), ... that Adam Singer, M.D., Chairman and CEO of IPC The ... and Modern Physician as one of the ... released by the publications on Monday, May 11th.Jeffrey Taylor, IPC,s ...
    ... of a landmark drug comparison study published in 2002 in ... for high blood pressure. A scientific team including investigators from ... the findings in the May 11 issue of the ... adults in the United States has high blood pressure, which, ...
    ... Sunday, May 17, traffic near the University of Washington ... for the 27th annual Nordstrom Beat the Bridge to Beat ... Montlake Closures , From 7:30 a.m. until ... Street to 44th Avenue NE. 520 Ramp Closures ...
    Cached Medicine News:Health News:$10 Million Gift to Transform Neuromedicine at URMC 2Health News:$10 Million Gift to Transform Neuromedicine at URMC 3Health News:$10 Million Gift to Transform Neuromedicine at URMC 4Health News:$10 Million Gift to Transform Neuromedicine at URMC 5Health News:AMTA Applauds Craigslist Decision, Calls for Protection of Massage Therapists 2Health News:IPC The Hospitalist Company CEO Adam Singer Named One of 50 Most Powerful Physician Executives 2Health News:New research confirms milestone study on blood pressure meds 2Health News:New research confirms milestone study on blood pressure meds 3Health News:Nordstrom Beat the Bridge to Beat Diabetes Run to Temporarily Suspend Traffic in University District on Sunday, May 17 2
    ... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
    ... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
    ... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
    ... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
    Medicine Products: